

Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi. We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

**Cais Rhyddid Gwybodaeth / Freedom of Information request**  
**Ein Cyf / Our Ref: 23-D-027**

**You asked:**

**Please may you tell me how many patients were initiated with each drug and indication/form below**

**Data periods:**

- **Monthly from January 2022 to February 2023**
- **Total yearly 2020, 2021 and 2022, for each drug and indication/form above**

Title	NICE TA Codes	Jan/Feb/Mar 2023 (Total)	2020	2021	2022
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer	TA831	0	0	0	0
Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer	TA693	<5* all months	0	0	<5*
Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer	TA620	<5* all months	6	6	6
Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy	TA598	**	**	**	**
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection	TA761	<5* all months	0	0	0



Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer	TA653	**	**	**	**
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer	TA654	0	<5*	<5*	11
Acalabrutinib for treating chronic lymphocytic leukaemia	TA689	<5* all months	<5*	7	5
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation	TA798	<5* all months	5	6	10
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments	TA862	0	0	0	0
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies	TA704	<5* all months	0	<5*	<5*

\* Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

\*\* I can confirm that this information is not held centrally. To obtain this information would involve a manual trawl and search of records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act and The Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulation 2004 provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

